Atorvastatin in the Treatment of Mandibular Degree II Furcation Defects

Clinical Efficacy of Subgingivally Delivered Atorvastatin in the Treatment of Mandibular Degree II Furcation Defects: A Randomized Controlled Clinical Trial .

Status

Completed

Phases

Phase 2Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02386033

Enrollment

Registered

2015-03-11

Start date

2013-11-30

Completion date

2014-07-31

Last updated

2015-03-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Periodontitis

Brief summary

ABSTARCT Background: Atorvastatin is an inhibitor of 3-hydroxy-2-methyl-glutaryl coenzyme A reductase. Lately, it has shown to have anti-inflammatory and bone stimulatory effects. The aim of the current study is to explore the effectiveness of 1.2% atorvastatin (ATV) as an adjunct to scaling and root planning (SRP) in the treatment of mandibular degree II furcation defects. Method: A total of sixty subjects were randomly assigned to two treatment groups. 1. SRP plus placebo gel 2. SRP plus 1.2% ATV gel. Clinical parameters like probing depth (PD), relative vertical clinical attachment level (RVCAL) , relative horizontal clinical attachment level (RHCAL), modified sulcus bleeding index (mSBI) and site specific plaque index were recorded at baseline and then at 3, 6 and 9 months. The radiological assessment of bone defect fill was done at 6 and 9 months, using a computer-aided software.

Detailed description

Two groups were made. One was delivered with ATV after SRP, the other was delivered with placebo gel after SRP.

Interventions

DRUGAtorvastatin (ATV)

After SRP, ATV gel was delivered subgingivally into the pocket

DRUGPlacebo Gel

After SRP, placebo gel was delivered subgingivally into the pocket

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender

ALL

Age

30 Years to 45 Years

Healthy volunteers

Yes

Inclusion criteria

* lower first molars demonstrating a probing pocket depth of 5 mm and horizontal probing depth of 3 mm following phase 1 therapy, with furcation defects (degree II) present bucally in asymptomatic, vital lower first molars, with a furcation radiolucency on a periapical radiograph of the molars.

Exclusion criteria

* patients with systemic diseases like cardiovascular disease * diabetes or HIV infection or on medications like corticosteroids which may impede the healing in periodontal tissues. * pregnant/lactating females * tobacco users * alcoholics * patients with unsatisfactory oral hygiene (plaque index greater than 1.5) * teeth having gingival recession, caries involving pulp, intrabony defect present interproximally, grade 2/3 mobility * Furthermore, patients allergic to ATV or other statins or those taking ATV/other statins systemically were excluded.

Design outcomes

Primary

Measure	Time frame
amount of bone fill	baseline to 9 months

Secondary

Measure	Time frame
change in Relative vertical clinical attachment level	baseline to 9 months
change in RHCAL (relative horizontal clinical attachment level)	baseline to 9 months
change in probing depth	baseline to 9 months
change in site specific plaque index	baseline to 9 months
change in modified sulcus bleeding index	baseline to 9 months

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026